Polygenic scores in cancer

Since the publication of the first genome-wide association study for cancer in 2007, thousands of common alleles that are associated with the risk of cancer have been identified. The relative risk associated with individual variants is small and of limited clinical significance. However, the combine...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Cancer Jg. 23; H. 9; S. 619 - 630
Hauptverfasser: Yang, Xin, Kar, Siddhartha, Antoniou, Antonis C., Pharoah, Paul D. P.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 01.09.2023
Nature Publishing Group
Schlagworte:
631/67/2322
631/67/68
692/499
Alleles
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Clinical Relevance
Clinical trials
Genome-wide association studies
Genome-Wide Association Study
Genomes
Humans
Neoplasms - genetics
Prediction models
Review Article
Reviews
Therapeutic applications
ISSN:1474-175X, 1474-1768, 1474-1768
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Since the publication of the first genome-wide association study for cancer in 2007, thousands of common alleles that are associated with the risk of cancer have been identified. The relative risk associated with individual variants is small and of limited clinical significance. However, the combined effect of multiple risk variants as captured by polygenic scores (PGSs) may be much greater and therefore provide risk discrimination that is clinically useful. We review the considerable research efforts over the past 15 years for developing statistical methods for PGSs and their application in large-scale genome-wide association studies to develop PGSs for various cancers. We review the predictive performance of these PGSs and the multiple challenges currently limiting the clinical application of PGSs. Despite this, PGSs are beginning to be incorporated into clinical multifactorial risk prediction models to stratify risk in both clinical trials and clinical implementation studies. Since the advent of genome-wide association studies, thousands of common alleles have been linked with the risk of cancer. Here, Yang et al. review the development, utility and predictive power of polygenic risk scores and the ongoing debate about their potential for clinical application in cancer.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1474-175X
1474-1768
1474-1768
DOI:10.1038/s41568-023-00599-x